Your best medicine news resource
Apr 11th 2008Drug InformationCystic Fibrosis
Illinois and Vermont have joined 37 other states and the District of Columbia in requiring that all newborns be screened for cystic fibrosis at birth. In addition, the Nevada Department of Health has decided to begin regular CF screening as well. Routine screening will be implemented when state lawmakers set an implementation date.
More: continued here
Apr 11th 2008Drug InformationCystic Fibrosis
Dry airways may not only play a central role in the development of the in-herited lung disease cystic fibrosis, but also in much more common acquired chronic lung diseases such as asthma and smoker’s lung, the ciga-rette smoke-induced chronic obstructive pulmonary disease (COPD). This is the conclusion reached by scientists at Heidelberg University Hospital under the direction of Assistant Professor Dr.
More: continued here
Apr 3rd 2008Drug InformationCystic Fibrosis
KaloBios Pharmaceuticals, Inc., a privately held biopharmaceutical company, announced the initiation of a Phase 1/2 clinical trial of KB001, a Humaneered?, high-affinity antibody fragment that KaloBios is developing for the treatment of P. aeruginosa infections. The trial is being conducted in conjunction with the Cystic Fibrosis Foundation and its affiliated organizations.
More: continued here
Apr 2nd 2008Drug InformationCystic Fibrosis
Responding to a study published in the New England Journal of Medicine, which concluded that lung transplants were harmful for children with cystic fibrosis, articles published in the latest issue of Pediatric Transplantation refute the conclusions and argue that the highly influential research was severely flawed. According to two rebuttals published in the acclaimed journal, the conclusions of the study on post-transplant survival rates led by Theodore G.
More: continued here
Apr 2nd 2008Drug InformationCystic Fibrosis
New U of T research holds promise for developing innovative therapies against cystic fibrosis and may also serve as a model for future therapies against the HIV virus. Led by Professor Igor Stagljar, University of Toronto scientists have identified several compounds that block activity of a key protein (exoenzymeS or ExoS).
More: continued here
Apr 2nd 2008Drug InformationCystic Fibrosis
“Drug ‘could aid cystic fibrosis’” is the headline on BBC News. The article says that “widely-used antidepressants could prevent infections which shorten the lives of many cystic fibrosis patients”. The report is based on the findings from a study in mice which has shed further light on the biological processes involved in the changes to the lungs caused by the cystic fibrosis mutation. Lung infections are a major cause of death in people who have cystic fibrosis.
More: continued here
Apr 2nd 2008Drug InformationCystic Fibrosis
The Cystic Fibrosis Foundation has announced that VX-770, an oral drug in development that targets a basic defect in CF, showed promising results in an ongoing Phase 2a clinical trial for patients who carry the G551D mutation of CF. The drug is being developed by Vertex Pharmaceuticals Incorporated.
More: continued here
Apr 2nd 2008Drug InformationCystic Fibrosis
The Cystic Fibrosis Foundation has announced that VX-770, an oral drug in development that targets a basic defect in CF, showed promising results in an ongoing Phase 2a clinical trial for patients who carry the G551D mutation of CF. The drug is being developed by Vertex Pharmaceuticals Incorporated.
More: continued here
Apr 2nd 2008Drug InformationCystic Fibrosis
The Cystic Fibrosis Foundation has announced the launch of a new $5 million initiative to enhance care for the growing adult CF population. The initiative, called the Program for Adult Care Excellence (PACE), will expand the scope of adult care programs for people with cystic fibrosis.The number of adults with cystic fibrosis continues to increase as life expectancy for the disease continues to rise.
More: continued here
Apr 2nd 2008Drug InformationCystic Fibrosis
Thousands of people will be taking steps to cure Cystic Fibrosis (CF) this year by taking part in a series of sponsored walks across the UK. Great Strides, sponsored by Solvay Healthcare, is a worldwide initiative to get people walking to help see off CF. The sponsored walks aim to raise funds to help the 8,000 people with CF in the UK look forward to a brighter future and a longer and better quality of life.
More: continued here
Your best medicine news resource
